- Telehealth visits
Maria I. Castellanos, MD
She | Her | HersPediatric Hematology-Oncology- Telehealth visits
Maria I. Castellanos, MD
She | Her | HersPediatric Hematology-Oncology- Telehealth visits
On this page
About me
Dr. Maria I. Castellanos is a pediatric hematologist-oncologist who cares for children and adolescents with various types of cancer and blood disorders. She is a native Spanish speaker.
In her research, Castellanos is interested in why different populations of children with cancer have different survival rates. She aims to elucidate the causes of cancer health disparities, reduce the survival gap and ensure equal access to treatment for all patients. In particular, she studies how geography and social determinants of health (nonmedical factors that affect wellness, such as housing and exposure to racism) impact childhood cancer survival.
Castellanos earned her medical degree at Howard University College of Medicine. She completed a residency in pediatrics at Lucile Packard Children's Hospital Stanford and a fellowship in pediatric hematology-oncology at Texas Children's Hospital, an affiliate of Baylor College of Medicine.
Education & training
Board certification
- Pediatric Hematology-Oncology, American Board of Pediatrics
- Pediatrics, American Board of Pediatrics
Fellowship
- Pediatric Hematology-Oncology, Baylor College of Medicine
Residency
- Pediatrics, Stanford Hospital and Clinics
Degree
- MD, Howard University College of Medicine
Academic Title
- Health Sciences Clinical Professor
My expertise
Specialties
- Pediatric Hematology-Oncology
Locations
My research
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.